Morgan Stanley Lowers Pharvaris (NASDAQ:PHVS) Price Target to $34.00

Pharvaris (NASDAQ:PHVS) had its price objective lowered by Morgan Stanley from $35.00 to $34.00 in a research report released on Monday morning, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Several other research analysts have also issued reports on PHVS. Wedbush reissued an outperform rating and issued a $35.00 target price on shares of Pharvaris in a research report on Thursday, April 11th. JMP Securities increased their target price on Pharvaris from $49.00 to $50.00 and gave the stock a market outperform rating in a research report on Thursday, April 11th.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $21.20 on Monday. Pharvaris has a 52-week low of $7.93 and a 52-week high of $33.00. The firm has a market capitalization of $675.01 million, a P/E ratio of -7.46 and a beta of -3.12. The stock has a 50 day moving average price of $24.41 and a 200-day moving average price of $23.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. Bank of America Corp DE increased its position in Pharvaris by 1,054.4% during the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company’s stock valued at $105,000 after buying an additional 5,272 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Pharvaris by 2.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company’s stock valued at $1,259,000 after buying an additional 1,115 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in Pharvaris during the 3rd quarter valued at approximately $26,000. UBS Group AG bought a new position in Pharvaris during the 4th quarter valued at approximately $32,000. Finally, Morgan Stanley increased its position in Pharvaris by 99.9% during the 4th quarter. Morgan Stanley now owns 38,180 shares of the company’s stock valued at $430,000 after buying an additional 19,085 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).